

# Emili Montserrat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3769200/publications.pdf>

Version: 2024-02-01

137  
papers

10,869  
citations

100601

38  
h-index

35168

102  
g-index

141  
all docs

141  
docs citations

141  
times ranked

10119  
citing authors

#	ARTICLE	IF	CITATIONS
1	mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2022, 108, 264-267.	1.1	7
2	Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 216-223.	0.2	13
3	Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. <i>Leukemia</i> , 2021, 35, 2325-2331.	3.3	13
4	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 328-333.	1.0	7
5	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	1.3	6
6	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
7	When CLL meets COVID-19. <i>Blood</i> , 2020, 136, 1115-1116.	0.6	11
8	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	1.2	18
9	CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. <i>Leukemia</i> , 2020, 34, 1954-1956.	3.3	28
10	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
11	The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy. <i>Leukemia Research</i> , 2020, 95, 106401.	0.4	7
12	FcγRIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 106, 306-309.	1.7	1
13	Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2020, 104, 512-515.	1.1	5
14	Comparison between Time-Limited, Venetoclax-Based and Continuous Bruton Tyrosine Kinase Inhibitors-Based Therapy in the Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): a Systematic Review and Network Meta-Analysis. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
15	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
16	Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study. <i>British Journal of Haematology</i> , 2019, 185, 148-150.	1.2	2
17	Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty. <i>Cancer</i> , 2019, 125, 3699-3705.	2.0	11
18	Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia. <i>Lancet Haematology</i> , 2019, 6, e65-e66.	2.2	1

#	ARTICLE	IF	CITATIONS
19	Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 423-430.	0.2	28
20	Upfront Therapy with Ibrutinib Results in a Longer Progression-Free Survival Independently of IGHV Mutational Status and Del(11q) in CLL Patients. Results of a Comprehensive Review and Meta-Analysis. <i>Blood</i> , 2019, 134, 5469-5469.	0.6	0
21	Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2018, 8, 10.	2.8	6
22	Critical molecular pathways in CLL therapy. <i>Molecular Medicine</i> , 2018, 24, 9.	1.9	33
23	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
24	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 121-128.	0.7	133
25	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , 2018, 132, 892-902.	0.6	83
26	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018, 132, 1834-1834.	0.6	1
27	CLL: when the target of treatment is disease-related symptoms. <i>Lancet Haematology</i> , 2017, 4, e57-e58.	2.2	0
28	Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (<sc><i>IGHV</i></sc> mutational status and <sc>FISH</sc> cytogenetics) separates patients with different outcome and simplifies the <sc>CLL</sc>. <i>American Journal of Hematology</i> , 2017, 92, 375-380.	2.0	79
29	Reliability of six prognostic models to predict time to first treatment in patients with chronic lymphocytic leukaemia in early phase. <i>American Journal of Hematology</i> , 2017, 92, E91-E93.	2.0	12
30	FcγRIIb expression in early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2642-2648.	0.6	7
31	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
32	Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?. <i>Haematologica</i> , 2016, 101, 263-265.	1.7	19
33	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
34	<sc>CD</sc>49d (<sc>ITGA</sc>4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated <i>IGHV</i> status. <i>British Journal of Haematology</i> , 2016, 172, 48-55.	1.2	23
35	Present and future of personalized medicine in CLL. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 100-110.	0.7	13
36	Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S74-S81.	0.2	18

#	ARTICLE	IF	CITATIONS
37	Maintenance therapy in chronic lymphocytic leukaemia. <i>Lancet Haematology</i> , 2016, 3, e399-e400.	2.2	0
38	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	0.6	0
39	Changes in Clinical Stage Identify Different Response Categories Among Patients in Iwcll PR: Analysis of CLL Patients on the Resonate Study. <i>Blood</i> , 2016, 128, 4384-4384.	0.6	0
40	Hope for High-Risk Chronic Lymphocytic Leukemia Relapsing After Allogeneic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2015, 33, 1527-1529.	0.8	6
41	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	1.7	42
42	Primary CNS lymphoma: in search of the evidence. <i>Lancet Haematology</i> , 2015, 2, e227-e228.	2.2	3
43	Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 59-64.	1.2	13
44	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. <i>Blood</i> , 2015, 126, 4146-4146.	0.6	2
45	Fcgammarib Expression As a Prognostic Marker in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1727-1727.	0.6	0
46	Prognostic factors in chronic lymphocytic leukemia: a conceptual approach. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 145-152.	0.7	1
47	Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 73-79.	0.2	4
48	B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. <i>British Journal of Haematology</i> , 2014, 164, 570-578.	1.2	32
49	New treatment options for chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 823-832.	0.9	7
50	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , 2014, 99, 1285-1291.	1.7	2
51	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. <i>Blood</i> , 2014, 124, 3841-3849.	0.6	185
52	Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. <i>Haematologica</i> , 2014, 99, 1599-1604.	1.7	56
53	Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 3951-3959.	0.6	55
54	MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 2016-2022.	0.6	26

#	ARTICLE	IF	CITATIONS
55	Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. , 2013, , 65-82.		0
56	PTLD treatment: a step forward, a long way to go. <i>Lancet Oncology</i> , The, 2012, 13, 120-121.	5.1	5
57	NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1064-1065.	1.5	0
58	A new genetic abnormality leading to <i>TP53</i> gene deletion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 156, 612-618.	1.2	7
59	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011, 475, 101-105.	13.7	1,364
60	Autografting CLL: the game is over!. <i>Blood</i> , 2011, 117, 6057-6058.	0.6	12
61	Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. <i>British Journal of Haematology</i> , 2011, 154, 14-22.	1.2	68
62	Chronic lymphocytic leukemia and autoimmunity: a systematic review. <i>Haematologica</i> , 2011, 96, 752-761.	1.7	117
63	The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years. <i>Blood</i> , 2011, 118, 1593-1593.	0.6	4
64	Response: Defining response criteria in CLL patients treated in clinical research trials. <i>Blood</i> , 2010, 116, 1817-1818.	0.6	1
65	Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. <i>Blood</i> , 2010, 116, 4771-4776.	0.6	126
66	Preface. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 1-2.	0.7	0
67	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. <i>Blood</i> , 2010, 116, 432-432.	0.6	5
68	B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. <i>Leukemia and Lymphoma</i> , 2009, 50, 1075-1082.	0.6	20
69	Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4578-4584.	0.8	116
70	Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. <i>Blood</i> , 2009, 114, 2945-2951.	0.6	157
71	p53 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective BTK Kinase Inhibitor BMS-345541. <i>Clinical Cancer Research</i> , 2009, 15, 2767-2776.	3.2	31
72	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Cl�nic of Barcelona experience. <i>Blood</i> , 2009, 114, 2044-2050.	0.6	132

#	ARTICLE	IF	CITATIONS
73	Genetic lesions in chronic lymphocytic leukemia: clinical implications. <i>Current Opinion in Oncology</i> , 2009, 21, 609-614.	1.1	7
74	Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2611-2611.	0.6	0
75	T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.. <i>Blood</i> , 2009, 114, 1945-1945.	0.6	0
76	Chronic Lymphocytic Leukemia Apoptotic Cell Death Induced by Glucocorticoids Is Mediated by BIM and GILZ and Can Be Predicted by FKBP5 Basal Expression Levels.. <i>Blood</i> , 2009, 114, 1236-1236.	0.6	6
77	The Prognostic Significance of Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2361-2361.	0.6	0
78	New prognostic markers in chronic lymphocytic leukemia. <i>Blood Reviews</i> , 2008, 22, 211-219.	2.8	118
79	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute's Working Group 1996 guidelines. <i>Blood</i> , 2008, 111, 5446-5456.	0.6	2,887
80	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2008, 68, 10178-10186.	0.4	67
81	Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling. <i>Clinical Cancer Research</i> , 2008, 14, 6907-6915.	3.2	69
82	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2008, 93, 1843-1851.	1.7	20
83	Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. <i>Clinical Cancer Research</i> , 2008, 14, 155-161.	3.2	117
84	Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. <i>Haematologica</i> , 2008, 93, 75-82.	1.7	22
85	Formin-Like Gene Expression in Chronic Lymphocytic Leukemia Is Associated with Unfavorable Prognostic Factors and Clinical Outcome. <i>Blood</i> , 2008, 112, 4181-4181.	0.6	0
86	No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 3615-3615.	0.6	5
87	Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 1576-1580.	0.8	54
88	The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 529-543.	0.7	9
89	BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2007, 110, 3464-3464.	0.6	1
90	Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 1141-1141.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Hematopoietic miRNAs Expression in Myelodysplastic Syndromes.. Blood, 2007, 110, 2422-2422.	0.6	0
92	Genetic Polymorphisms in the Inflammasomes Are Associated with Relapse and Survival in HLA-Identical Sibling Donor Allogeneic Stem Cell Transplantation.. Blood, 2007, 110, 1075-1075.	0.6	5
93	Mir-135a Expression Is Associated with Relapse in Hodgkin Lymphoma.. Blood, 2007, 110, 2270-2270.	0.6	0
94	MicroRNA Analysis by In Situ Hybridization in Hodgkin Lymphoma.. Blood, 2007, 110, 2271-2271.	0.6	0
95	How I treat refractory CLL. Blood, 2006, 107, 1276-1283.	0.6	85
96	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood, 2006, 107, 4563-4569.	0.6	130
97	Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. Cytometry Part B - Clinical Cytometry, 2006, 70B, 214-217.	0.7	26
98	New Prognostic Markers in CLL. Hematology American Society of Hematology Education Program, 2006, 2006, 279-284.	0.9	67
99	Over 20% of Patients with Chronic Lymphocytic Leukemia Carry Stereotyped Receptors: Pathogenetic Implications and Clinical Correlations.. Blood, 2006, 108, 26-26.	0.6	1
100	Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. , 2006, , 406-414.		0
101	Effect of Germline Polymorphisms on Clinical Outcome in Hodgkin's Lymphoma (HL).. Blood, 2006, 108, 2267-2267.	0.6	0
102	Analysis of microRNA Patterns in Hodgkin's Lymphoma (HL).. Blood, 2006, 108, 474-474.	0.6	0
103	Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood, 2005, 105, 1678-1685.	0.6	180
104	CLL therapy: progress at last!. Blood, 2005, 105, 2-3.	0.6	7
105	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. Journal of Pathology, 2005, 205, 507-513.	2.1	73
106	Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3433-3438.	0.8	137
107	Treatment of Chronic Lymphocytic Leukemia: Achieving Minimal Residual Disease's Negative Status As a Goal. Journal of Clinical Oncology, 2005, 23, 2884-2885.	0.8	34
108	Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research. Journal of Clinical Oncology, 2005, 23, 5788-5794.	0.8	104

#	ARTICLE	IF	CITATIONS
109	Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. <i>Blood</i> , 2005, 107, 859-861.	0.6	140
110	Impact of Dendritic Cell CD16+ Recovery on Outcome after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1409-1409.	0.6	0
111	Expression of Specialized Error-Prone DNA Polymerases in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 2941-2941.	0.6	0
112	Polymorphisms of NOD2/CARD15 Are Associated with Clinical Outcome in T-Cell Depleted HLA-Identical Sibling Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1408-1408.	0.6	0
113	Dexamethasone Induces Apoptosis <i>in Vivo</i> in Chronic Lymphocytic Leukemia Cells with Either Unmutated IgVH Genes or High ZAP-70 Expression.. <i>Blood</i> , 2005, 106, 2945-2945.	0.6	0
114	Cytosolic Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 2108-2108.	0.6	0
115	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. <i>Blood</i> , 2005, 106, 3009-3009.	0.6	0
116	Nucleotide Insertions and Deletions in Chronic Lymphocytic Leukemia. A CLL Specific Deletion among IGHV3-21 Expressing Cases with Stereotyped Receptors.. <i>Blood</i> , 2005, 106, 2100-2100.	0.6	0
117	Treatment options in chronic lymphocytic leukemia. <i>The Hematology Journal</i> , 2004, 5, S2-S9.	2.0	12
118	Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 915-926.	0.9	16
119	Clinical Characteristics and Outcome of a Large Series of Patients with Chronic Lymphocytic Leukemia (CLL) According to ZAP-70 Expression.. <i>Blood</i> , 2004, 104, 14-14.	0.6	4
120	Donor's Mannan-Binding Lectin (MBL) Gene Polymorphism Is Associated with Invasive Fungal Infection Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2220-2220.	0.6	2
121	Prognostic Indicators of Chronic Lymphocytic Leukemia. , 2004, , 201-215.		1
122	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. <i>Blood</i> , 2004, 104, 2054-2054.	0.6	0
123	Equilibrative Nucleoside Transporter-2 (ENT2) Protein Correlates with Ex-Vivo Sensitivity to Fludarabine in Chronic Lymphocytic Leukemia (CLL)-Cells.. <i>Blood</i> , 2004, 104, 2079-2079.	0.6	0
124	Rituximab in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2003, 30, 34-39.	0.8	24
125	ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 1764-1775.	13.9	1,194
126	Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. <i>British Journal of Haematology</i> , 2002, 119, 484-487.	1.2	10



#	ARTICLE	IF	CITATIONS
127	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 976-984.	1.2	163
128	Current and Developing Chemotherapy for CLL. <i>Medical Oncology</i> , 2002, 19, S11-S20.	1.2	11
129	Classical and new prognostic factors in chronic lymphocytic leukemia: Where to now?. <i>The Hematology Journal</i> , 2002, 3, 7-9.	2.0	35
130	Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2001, 113, 422-424.	1.2	73
131	cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. , 2000, 89, 148-152.		56
132	Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 1992, 81, 391-394.	1.2	140
133	Clinical features and response to treatment of infradiaphragmatic Hodgkin's disease. <i>European Journal of Haematology</i> , 1991, 46, 38-41.	1.1	11
134	A new prognostic system for multiple myeloma based on easily available parameters. <i>British Journal of Haematology</i> , 1989, 72, 507-511.	1.2	39
135	IMPACT OF RENAL FUNCTION ON THE MYELOMA STAGING. <i>Scandinavian Journal of Haematology</i> , 1984, 33, 399-400.	0.0	0
136	Cross-resistance to alkylating agents in multiple myeloma. <i>Cancer</i> , 1983, 52, 786-789.	2.0	15
137	Prognosis in Acquired Aplastic Anaemia A Multivariate Statistical Analysis of 80 Cases. <i>Scandinavian Journal of Haematology</i> , 1981, 26, 321-329.	0.0	10